Tolerability to enoxaparine for DVT prophylaxis in patients undergoing total hip arthroplasty

Emre Togrul; Yaman Sarpel; Gurbuz Baytok; Ismet Tan; Serdar Ozbarlas

Article Details

Tolerability to enoxaparine for DVT prophylaxis in patients undergoing total hip arthroplasty

Authors:

Emre Togrul | Yaman Sarpel | Gurbuz Baytok | Ismet Tan | Serdar Ozbarlas

Publisher:

Turkish Association of Orthopaedics and Traumatology

Journal:

Acta Orthopaedica et Traumatologica Turcica 1997 Vol.31 Issue 2, pp.94-96

Document Type:

Article

Publication Date:

9/2006

Document Language:

English

Document ID (Org No.):

2000814180

Frequency:

Bimonthly

eISSN:

1017-995X

pISSN:

1017-995X

Keywords:

-

Abstract:

 

From April 1994 to August 1995, thirty consecutive patients who underwent total hip arthroplasty were managed with enoxaparine; in order to evaluate the prophylactic effect of low molecular weight heparin in high risk patients. Patients who were not having appropriate criteria for the usage of enoxaparine excluded from the study. There were 12 (%40) females and 18 (60) males with a mean age of 50.38 (range 40-78). Primary osteoarthritis in 22, rheumatoid arthritis in 6, and dysplastic hip in 2 patients were the indications of total hip replacement. Age, sex, height, weight, total biochemical analysis of each patient and schedule for drug were noted. First dose of enoxaparine was administered 12 hours before the operation and 0.4 ml (40 mg) daily dose was continued up to postoperative eleventh  day. Pain, local allergic reactions, haematoma in the injection site and abnormal bleeding from the operation site were followed. No  DVT or complication of injection was observed. As a result, prophylaxis of DVT with daily 40 mg of enoxaparine is a feasible, safe and effective procedure in high risk patients who underwent total hip arthroplasty.

 

Derin ven trombozu (DVT) riski taşıyan ve total kalça artroplastisi gibi majör bir ameliyatla bu riskin arttığı hastalarda düşük molekül ağırlıklı heparinin proflaktik etkisini araştırmak amacıyla Nisan, 1994-Ağustos 1995 tarihleri arasında total kalça protezi uygulanan 30 hasta enoksaparin proflaksisine alındı. İlaç kullanım kriterleri belirlenip kriter dışı kalan hastalarda uygulama yapılmadı. Hastalarımızın 12 (%40)'sı kadın, 18 (%60)’ı erkek olup yaş ortalaması 50.38 (40-78) idi. 22 hastaya primer osteoartrit, 6 hastaya romatoid artrit. 2 hastaya displazik kalça nedeniyle total kalça protezi uygulaması yapıldı. Hastaların yaş, cins, boy, kilo, tüm kan biyokimyası ile ilacın başlama, dozaj ve kullanım şemaları kaydedildi. Enoksaparin uygulaması operasyondan 12 saat önce başlatıldı ve 0.4 ml (40 mg) gün pozolojisi'nde 11 gün süreyle uygulandı. Hastalar enjeksiyon bölgesinde ağrı, lokal allerjik reaksiyonlar, hematom varlığı, peroperatif ve postoperatif anormal kanamalar açısın-dan takip edildi. Hiçbir hastada derin ven trombozu ya da enjeksiyona bağlı komplikasyon gelişmedi. Sonuç olarak 40 mg/gün enoksaparin ile yapılan derin ven tromboz proflaksisinin total kalça protezi uygulanan hastalar-da kolay uygulanabilen, güvenli ve etkili bir yöntem olduğu sonucuna varıldı.

Article Details

Tolerability to enoxaparine for DVT prophylaxis in patients undergoing total hip arthroplasty

Authors: Emre Togrul | Yaman Sarpel | Gurbuz Baytok | Ismet Tan | Serdar Ozbarlas

Publisher: Turkish Association of Orthopaedics and Traumatology

Journal: Acta Orthopaedica et Traumatologica Turcica 1997 Vol.31 Issue 2, pp.94-96

Document Type: Article

Publication Date: 9/2006

Document Language: English

Document ID (Org No.): 2000814180

Frequency: Bimonthly

eISSN: 1017-995X

pISSN: 1017-995X

-

Issues

Authors:

Emre Togrul | Yaman Sarpel | Gurbuz Baytok | Ismet Tan | Serdar Ozbarlas

Publisher:

Turkish Association of Orthopaedics and Traumatology

Journal:

Acta Orthopaedica et Traumatologica Turcica 1997 Vol.31 Issue 2, pp.94-96

Document Type:

Article

Publication Date:

9/2006

Document Language:

English

Document ID (Org No.):

2000814180

Frequency:

Bimonthly

eISSN:

1017-995X

pISSN:

1017-995X